SAN DIEGO, March 24 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today highlighted its financial results and product development progress for the year ended December 31, 2008.
“Prometheus had another record year in 2008, our 12th consecutive year of sales growth,” said Joseph M. Limber, President and Chief Executive Officer of Prometheus. “In addition, we made significant progress advancing a number of internal development programs, all of which we believe will help to strongly position us for future growth. We continue to pursue additional opportunities through product licensing or acquisition or through strategic mergers or acquisitions. We are also preparing to expand into additional commercially attractive therapeutic areas, including oncology, that are consistent with our unique business model of offering proprietary and complementary pharmaceutical and diagnostic products.”
Financial Highlights
Product Development Highlights
About Prometheus
Prometheus Laboratories Inc. is a specialty pharmaceutical and diagnostic company committed to developing and commercializing novel pharmaceutical and diagnostic products to help physicians individualize patient care. Prometheus is currently focused on the detection, diagnosis and treatment of gastrointestinal diseases and disorders in the United States. Its strategy includes the marketing and delivery of pharmaceutical products complemented by proprietary, high-value diagnostic testing services. By integrating pharmaceutical products and diagnostic testing services, Prometheus believes it can address the full continuum of care, thereby providing physicians with a comprehensive solution to treat chronic diseases. Prometheus’ corporate offices are located in San Diego, California.
CONTACT: Pete De Spain, Director, Investor Relations & Corporate
Communications of Prometheus Laboratories Inc., +1-858-587-4117,
pdespain@prometheuslabs.com
Web site: http://www.prometheuslabs.com/
